ASK REDCHAT ANYTHING ABOUT MATINAS BIOPHARMA HOLDINGS INC.
Matinas Biopharma Holdings Inc. (NYSE AMERICAN: MTNB)
Listen to this Section
$0.79
-0.0090
(
-1.12% )
10.8K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| MAT2203 (Oral Amphotericin B)DetailsMeningitis, Cryptococcal meningitis, Azole-resistant infections, C. krusei infection, Fungal infections, Invasive Aspergillosis |
Failed |
| LYPDISO (MAT9001) (Omega-3 Drug)DetailsCardiovascular disease |
Failed |
Market Data
|
| Open |
$0.79 |
| Previous Close |
$0.80 |
| Volume |
10.8K |
| Market Cap |
$4.98M |
| Day Range |
$0.77 - $0.82 |
| 52 Week Range |
$0.48 - $3.09 |
| Shares Outstanding |
6.41M |
| Change % |
-1.12% |
| Net Change |
▼ -0.0090 |
| Insider Ownership |
N/A |
| Exchange |
NYSE AMERICAN |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2014 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased:
-11,623,464.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-11-03 |
Sale |
-437244.00 |
CONRAD HERBERT J |
| 2023-11-03 |
Sale |
-437244.00 |
Ende Eric J |